VIKING GLOBAL INVESTORS LP 13D and 13G filings for Amylyx Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 10:24 am Sale | 2023-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VIKING GLOBAL INVESTORS LP | 2,962,555 4.400% | -1,672,051 (-36.08%) | Filing |
| 2023-02-14 1:18 pm Sale | 2022-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VIKING GLOBAL INVESTORS LP | 4,634,606 7.000% | -1,135,930 (-19.68%) | Filing |
| 2022-09-09 9:50 pm Sale | 2022-09-08 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VIKING GLOBAL INVESTORS LP | 5,770,536 9.900% | -1,400,000 (-19.52%) | Filing |
| 2022-01-21 5:05 pm Purchase | 2022-01-11 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VIKING GLOBAL INVESTORS LP | 7,170,536 12.400% | 7,170,536 (New Position) | Filing |